For Physicians

PD-1 Blockade in Classical Hodgkin Lymphoma

Using the power of the human immune system to combat cancer has been a long-standing goal in oncology. In the last few years, an important milestone on the way to this goal has been the understanding of immune checkpoint pathways.

Immunomodulation in Multiple Myeloma

Effective cancer immunotherapy represents a major paradigm shift in the treatment of solid and hematologic malignancies. From the development of monoclonal antibodies (MoAb) to antibody-drug conjugates targeting cancer-associated epitopes until the most recent checkpoint blockade and bioengineered chimeric antigen receptor (CAR) T cells, the natural history of several types of cancer has been radically impacted by these treatments.

Clinical Trial Spotlight-Trial #12-537 Ipilimumab for Patients Who Relapse after Allogeneic Transplantation

Patients with hematologic malignancies who relapse after allogeneic transplantation have few effective therapeutic options and generally have a poor prognosis.

Research Spotlight: New Frontiers in Cellular Therapies – 360 Degrees of Immuno-oncology

Allogeneic hematopoietic stem cell transplantation (HSCT) is the original cellular therapy. When HSCT is used for treatment of patients with leukemia and other hematologic malignancies, clinicians hope that polyclonal T cells from healthy donors will recognize tumor cells that the patient's own T cells do not, thereby exerting an anti-neoplastic "graft-versus-leukemia" (GvL) effect.

Hematologic Malignancies: Physician Resources

If you are a clinician specializing in the field of hematologic oncology, we can help you refer a patient, explore open clinical trials, learn about CME events, and more.

View our full list of hematologic malignancies resources for referring providers.